DOI QR코드

DOI QR Code

우리나라의 다제약제 현황과 적정관리 방안에 대한 고찰

Reviews on the Current Status and Appropriate Management of Polypharmacy in South Korea

  • 투고 : 2017.12.06
  • 심사 : 2018.01.15
  • 발행 : 2018.03.02

초록

Polypharmacy is increasing owing to an increase in the elderly population and multimorbidities associated with the increased risk of administration of potentially inappropriate medications (PIMs). The negative effects of polypharmacy on various health conditions and aspects, such as fall, fracture, mortality, cognitive function, and dementia, have been reported. The management of excess and inappropriate polypharmacy through proper interventions and local or national guidelines has been highlighted. The purpose of polypharmacy management is to appropriately prescribe medicines that are essential to treat diseases in patients and to avoid inappropriate polypharmacy, such as interactive or duplicate medicines under prescription and PIMs for specific diseases. Community pharmacists in Australia, the EU, USA, and Japan are collaborating with prescribers to review medications to ensure that the patients can be prescribed appropriate medications. The service cost is reimbursed by public or private insurers. A study in the United States has shown that even with medication review costs, the overall medication cost has reduced. In Korea, various projects such as Drug Utilization Review service and safe use of medicines have been conducted; however, no national guidelines or management measures have been established. It is necessary to implement a national long-term plan on polypharmacy management. Furthermore, a phased implementation plan is required. Shortly, active medication review services and education programs for healthcare professionals with the support of the government should be considered in Korea with reference to other countries in order to raise awareness of seriousness and risks of inappropriate polypharmacy.

키워드

참고문헌

  1. World Health Organization: Ageing and Health Technical Report Vol. 5: A Glossary of Terms for Community Health Care and Services for Older Persons. In.; 2004.
  2. Mortazavi SS, Shati M, Keshtkar A, et al. Defining polypharmacy in the elderly: a systematic review protocol. BMJ Open 2016;6(3):e010989. https://doi.org/10.1136/bmjopen-2015-010989
  3. Herr M, Robine JM, Pinot J, et al. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf 2015;24(6):637-46. https://doi.org/10.1002/pds.3772
  4. Jyrkka J, Enlund H, Lavikainen P, et al. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 2011;20(5):514-22. https://doi.org/10.1002/pds.2116
  5. Nobili A, Pasina L, Tettamanti M, et al. Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database. J Clin Pharm Ther 2009; 34(4):377-86. https://doi.org/10.1111/j.1365-2710.2009.01021.x
  6. Wang R, Chen L, Fan L, et al. Incidence and Effects of Polypharmacy on Clinical Outcome among Patients Aged 80+: A Five-Year Follow-Up Study. PLoS One 2015; 10(11):e0142123. https://doi.org/10.1371/journal.pone.0142123
  7. Fried TR, O'Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 2014; 62(12):2261-72. https://doi.org/10.1111/jgs.13153
  8. Park HY, Park JW, Song HJ, et al. The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea. PLoS One 2017;12(1):e0169463. https://doi.org/10.1371/journal.pone.0169463
  9. Park HY, Park JW, Sohn HS, et al. Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea. Drug Saf 2017.
  10. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17(1):230.
  11. Kim HA, Shin JY, Kim MH, et al. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One 2014; 9(6):e98043. https://doi.org/10.1371/journal.pone.0098043
  12. Nam YS, Han JS, Kim JY, et al. Prescription of potentially inappropriate medication in Korean older adults based on 2012 Beers Criteria: a cross-sectional population based study. BMC Geriatr 2016; 16:118. https://doi.org/10.1186/s12877-016-0285-3
  13. Park HY, Ryu HN, Shim MK, et al. Prescribed drugs and polypharmacy in healthcare service users in South Korea: an analysis based on National Health Insurance Claims data. Int J Clin Pharmacol Ther 2016; 54(5):369-77. https://doi.org/10.5414/CP202484
  14. McCracken R, McCormack J, McGregor MJ, et al. Associations between polypharmacy and treatment intensity for hypertension and diabetes: a cross-sectional study of nursing home patients in British Columbia, Canada. BMJ Open 2017; 7(8):e017430.
  15. Saum KU, Schottker B, Meid AD, et al. Is Polypharmacy Associated with Frailty in Older People? Results From the ESTHER Cohort Study. J Am Geriatr Soc 2017; 65(2):e27-e32. https://doi.org/10.1111/jgs.14718
  16. Moriarty F, Hardy C, Bennett K, et al. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open 2015; 5(9):e008656. https://doi.org/10.1136/bmjopen-2015-008656
  17. Beer C, Hyde Z, Almeida OP, et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study. Br J Clin Pharmacol 2011; 71(4):592-9. https://doi.org/10.1111/j.1365-2125.2010.03875.x
  18. Franchi C, Cartabia M, Risso P, et al. Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project. Eur J Clin Pharmacol 2013;69(7):1477-83. https://doi.org/10.1007/s00228-013-1495-7
  19. Niikawa H, Okamura T, Ito K, et al. Association between polypharmacy and cognitive impairment in an elderly Japanese population residing in an urban community. Geriatr Gerontol Int 2017;17(9):1286-93. https://doi.org/10.1111/ggi.12862
  20. Sinnige J, Braspenning JC, Schellevis FG, et al. Inter-practice variation in polypharmacy prevalence amongst older patients in primary care. Pharmacoepidemiol Drug Saf 2016;25(9):1033-41. https://doi.org/10.1002/pds.4016
  21. Nishtala PS, Salahudeen MS. Temporal Trends in Polypharmacy and Hyperpolypharmacy in Older New Zealanders over a 9-Year Period: 2005-2013. Gerontology 2015;61(3):195-202. https://doi.org/10.1159/000368191
  22. Lu WH, Wen YW, Chen LK, et al. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ 2015;187(4):E130-7. https://doi.org/10.1503/cmaj.141219
  23. Charlesworth CJ, Smit E, Lee DS, et al. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci 2015;70(8):989-95. https://doi.org/10.1093/gerona/glv013
  24. Jang IY, Lee YS, Jeon MK, et al. Potentially Inappropriate Medications in Elderly Outpatients by the 2012 Version of Beers Criteria: A Single Tertiary Medical Center Experience in South Korea. J Korean Geriatr Soc 2013;17:126-33. https://doi.org/10.4235/jkgs.2013.17.3.126
  25. Kojima T, Akishita M, Nakamura T, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 2012;12(3):425-30. https://doi.org/10.1111/j.1447-0594.2011.00783.x
  26. Zia A, Kamaruzzaman SB, Tan MP. The consumption of two or more fall risk-increasing drugs rather than polypharmacy is associated with falls. Geriatr Gerontol Int 2017;17(3):463-70. https://doi.org/10.1111/ggi.12741
  27. Thorell K, Ranstad K, Midlov P, et al. Is use of fall risk-increasing drugs in an elderly population associated with an increased risk of hip fracture, after adjustment for multimorbidity level: a cohort study. BMC Geriatr 2014;14:131. https://doi.org/10.1186/1471-2318-14-131
  28. Laflamme L, Monarrez-Espino J, Johnell K, et al. Type, number or both? A population-based matched case-control study on the risk of fall injuries among older people and number of medications beyond fallinducing drugs. PLoS One 2015;10(3):e0123390.
  29. Richardson K, Ananou A, Lafortune L, et al. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging 2011;28(7):547-60. https://doi.org/10.2165/11592000-000000000-00000
  30. Lai SW, Lin CH, Liao KF, et al. Association between polypharmacy and dementia in older people: a population-based case-control study in Taiwan. Geriatr Gerontol Int 2012;12(3):491-8. https://doi.org/10.1111/j.1447-0594.2011.00800.x
  31. Aronson JK. In defence of polypharmacy. Br J Clin Pharmacol 2004; 57(2):119-20. https://doi.org/10.1111/j.1365-2125.2004.02067.x
  32. Aronson JK. Polypharmacy, appropriate and inappropriate. Br J Gen Pract 2006;56(528):484-45.
  33. Cole A, Wright H: The importance of 'appropriate' polypharmacy and the value of medicines. European Journal of Hospital Pharmacy 2017; 24(1):70-2.
  34. Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2014;10:CD008165.
  35. Oboh L, Qadir MS. Deprescribing and managing polypharmacy in frail older people: a patient-centred approach in the real world. European Journal of Hospital Pharmacy 2017;24(1):58-62. https://doi.org/10.1136/ejhpharm-2016-001008
  36. Cullinan S, Raae Hansen C, Byrne S, et al. Challenges of deprescribing in the multimorbid patient. European Journal of Hospital Pharmacy 2017; 24(1):43-6. https://doi.org/10.1136/ejhpharm-2016-000921
  37. Kuijpers MA, van Marum RJ, Egberts AC, et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008; 65(1):130-3. https://doi.org/10.1111/j.1365-2125.2007.02961.x
  38. Levy HB. Polypharmacy Reduction Strategies: Tips on Incorporating American Geriatrics Society Beers and Screening Tool of Older People's Prescriptions Criteria. Clin Geriatr Med 2017;33(2):177-187. https://doi.org/10.1016/j.cger.2017.01.007
  39. Barnett N, Jubraj B. A themed journal issue on deprescribing. European Journal of Hospital Pharmacy 2017;24(1):1-2. https://doi.org/10.1136/ejhpharm-2016-001118
  40. Scott I, Anderson K, Freeman C. Review of structured guides for deprescribing. European Journal of Hospital Pharmacy 2017;24(1):51-7. https://doi.org/10.1136/ejhpharm-2015-000864
  41. Bulajeva A, Labberton L, Leikola S, et al. Medication review practices in European countries. Res Social Adm Pharm 2014;10(5):731-40. https://doi.org/10.1016/j.sapharm.2014.02.005
  42. Kwon KH. A study on the pharmacy manpower project "Vision 2013"; A research report for the Ministry of Health and Welfare. In.; 2013.
  43. Mair A, Fernandez-Llimos F. Polypharmacy management programmes: the SIMPATHY Project. European Journal of Hospital Pharmacy 2017;24(1):5-6. https://doi.org/10.1136/ejhpharm-2016-001044
  44. Australian Government Department of Health. Medication management reviews. Online at. Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/medication_management_reviews.htm. Accessed September 28 2017.
  45. Chen TF. Pharmacist-Led Home Medicines Review and Residential Medication Management Review: The Australian Model. Drugs Aging 2016;33(3):199-204. https://doi.org/10.1007/s40266-016-0357-2
  46. Gilbert AL, Roughead EE, Beilby J, et al. Collaborative medication management services: improving patient care. Med J Aust 2002; 177(4):189-92.
  47. Emblen G, Miller E. Home medicines review. The how and why for GPs. Aust Fam Physician 2004;33(1-2):49-51.
  48. Dhillon AK, Hattingh HL, Stafford A, et al. General practitioners' perceptions on home medicines reviews: a qualitative analysis. BMC Fam Pract 2015;16:16. https://doi.org/10.1186/s12875-015-0227-8
  49. Dolovich L, Consiglio G, MacKeigan L, et al. Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013. Canadian Pharmacists Journal 2016;149(5):293-302.
  50. Barnett MJ, Frank J, Wehring H, et al. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. J Manag Care Pharm 2009;15(1):18-31.
  51. Matlin OS, Kymes SM, Averbukh A, et al. Community pharmacy automatic refill program improves adherence to maintenance therapy and reduces wasted medication. Am J Manag Care 2015;21(11):785-91.
  52. The Ministry of Health and Welfare. Drug Utilization Review; DUR system. Available from http://www.mohw.go.kr/front_new/policy/index.jsp?PAR_MENU_ID=06&MENU_ID=062904&PAGE=4. Accessed November 11, 2017.

피인용 문헌

  1. 약물 이행 모델 기반 다제약제 복용 노인의 약물 불이행과 관련 요인 vol.19, pp.12, 2019, https://doi.org/10.5392/jkca.2019.19.12.398
  2. 서울특별시 지역사회 거주 노인의 통합돌봄 요구 vol.10, pp.5, 2018, https://doi.org/10.22156/cs4smb.2020.10.05.177
  3. 갑상선 기능 저하 환자에서 levothyroxine 투여 시간에 따른 효능 비교: 메타분석 vol.30, pp.2, 2020, https://doi.org/10.24304/kjcp.2020.30.2.87
  4. Guidelines for Safe Drug Use vol.96, pp.3, 2021, https://doi.org/10.3904/kjm.2021.96.3.225